Contents

Search

aprocitentan (Tryvio)

Indications: - treatment-resistant hypertension in combination with other antihypertensives Contraindications: - pregnancy: embryo-fetal toxicity - breast feeding not advised Dosage: - 12.5 mg PO QD [1,2] (25 mg [1]) Adverse effects: - edema, fluid retention - anemia Mechanism of action: - endothelin receptor antagonist Notes: - prescribers must certify with the Tryvio Risk Evaluation & Mitigation Strategy program owing to the risk for embryo-fetal toxicity

Interactions

drug adverse effects of antihypertensive agents

General

endothelin receptor antagonist

References

  1. Brooks M FDA Okays New Drug for Resistant Hypertension. Medscape. March 20, 2024 https://www.medscape.com/viewarticle/fda-okays-new-drug-resistant-hypertension-2024a100058b
  2. Approved Tryvio label. Highlights of Prescribing Information TRYVIO (aprocitentan) tablets, for oral use U.S. Food and Drug Administration; 2024 Mar 19. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217686s000lbl.pdf